
Clinical Trial: Neuroendocrine Tumour (VMT-𝛼-NET) programs
Perspective Therapeutics Announces First Neuroendocrine Tumor Patients Dosed with Therapeutic IntentNovember 8, 2023SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), announced today that the first patient was dosed at Washington University in St Louis in the Company's Phase 1/2a trial evaluating the safety and efficacy of [212Pb]VMT-α-NET, a targeted alpha-particle therapy (TAT), in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT). Read announcement hereTargeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT)The Company's melanoma (VMT01) and neuroendocrine tumour (VMT-𝛼-NET) programs will then commence Phase 1/2a therapy trials for the treatment of…